Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07075640 | A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the Body in Healthy Participants | PHASE1 | ACTIVE NOT_RECRUITING | 24 | — | — | Jul 7, 2025 | Aug 31, 2026 | May 29, 2026 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Treatment Group A | EXPERIMENTAL | Participants will receive a single dose of AG-236 at dose level 1 or placebo on Day 1 under fasted conditions. |
| Treatment Group B | EXPERIMENTAL | Participants will receive a single dose of AG-236 at dose level 2 or placebo on Day 1 under fasted conditions. |
| Treatment Group C | EXPERIMENTAL | Participants will receive a single dose of AG-236 at dose level 3 or placebo on Day 1 under fasted conditions. |
| Name | Type | Description |
|---|---|---|
| AG-236 | DRUG | Subcutaneous (SC) Injection |
| Placebo | DRUG | SC Injection |
Inclusion Criteria * Male or female, of any race, between 18 and 55 years of age, inclusive. 1. Females must be of nonchildbearing potential. 2. Males must agree to use contraception. 3. Males must agree not to donate sperm during the study and for 90 days or 5-half-lives of AG-236 in plasma...